Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sohn, Bo Hwa | - |
dc.contributor.author | Shim, Jae-Jun | - |
dc.contributor.author | Kim, Sang-Bae | - |
dc.contributor.author | Jang, Kyu Yun | - |
dc.contributor.author | Kim, Soo Mi | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Hwang, Jun Eul | - |
dc.contributor.author | Jang, Hee-Jin | - |
dc.contributor.author | Lee, Hyun-Sung | - |
dc.contributor.author | Kim, Sang-Cheol | - |
dc.contributor.author | Jeong, Woojin | - |
dc.contributor.author | Kim, Sung Soo | - |
dc.contributor.author | Park, Eun Sung | - |
dc.contributor.author | Heo, Jeonghoon | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Kim, Dae-Ghon | - |
dc.contributor.author | Leem, Sun-Hee | - |
dc.contributor.author | Kaseb, Ahmed | - |
dc.contributor.author | Hassan, Manal M. | - |
dc.contributor.author | Cha, Minse | - |
dc.contributor.author | Chu, In-Sun | - |
dc.contributor.author | Johnson, Randy L. | - |
dc.contributor.author | Park, Yun-Yong | - |
dc.contributor.author | Lee, Ju-Seog | - |
dc.date.accessioned | 2021-09-04T01:56:47Z | - |
dc.date.available | 2021-09-04T01:56:47Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-03-01 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89253 | - |
dc.description.abstract | Purpose: The Hippo pathway is a tumor suppressor in the liver. However, the clinical significance of Hippo pathway inactivation in HCC is not clearly defined. We analyzed genomic data from human and mouse tissues to determine clinical relevance of Hippo pathway inactivation in HCC. Experimental Design: We analyzed gene expression data from Mst1/2(-/-) and Sav1(-/-) mice and identified a 610-gene expression signature reflecting Hippo pathway inactivation in the liver [silence of Hippo (SOH) signature]. By integrating gene expression data from mouse models with those from human HCC tissues, we developed a prediction model that could identify HCC patients with an inactivated Hippo pathway and used it to test its significance in HCC patients, via univariate and multivariate Cox analyses. Results: HCC patients (National Cancer Institute cohort, n = 113) with the SOH signature had a significantly poorer prognosis than those without the SOH signature [P < 0.001 for overall survival (OS)]. The significant association of the signature with poor prognosis was further validated in the Korean (n = 100, P = 0.006 for OS) and Fudan University cohorts (n = 242, P = 0.001 for OS). On multivariate analysis, the signature was an independent predictor of recurrence-free survival (HR, 1.6; 95% confidence interval, 1.12-2.28: P = 0.008). We also demonstrated significant concordance between the SOH HCC subtype and the hepatic stem cell HCC subtype that had been identified in a previous study (P < 0.001). Conclusions: Inactivation of the Hippo pathway in HCC is significantly associated with poor prognosis. Clin Cancer Res; 22(5); 1256-64. (C) 2015 AACR. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.subject | GENE-EXPRESSION | - |
dc.subject | ORGAN SIZE | - |
dc.subject | CANCER STATISTICS | - |
dc.subject | PREDICTION | - |
dc.subject | GROWTH | - |
dc.subject | CLASSIFICATION | - |
dc.subject | VARIANCE | - |
dc.subject | SURVIVAL | - |
dc.subject | SUBTYPES | - |
dc.subject | MARKERS | - |
dc.title | Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-15-1447 | - |
dc.identifier.scopusid | 2-s2.0-84962233261 | - |
dc.identifier.wosid | 000373355000025 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, v.22, no.5, pp.1256 - 1264 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.citation.title | CLINICAL CANCER RESEARCH | - |
dc.citation.volume | 22 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1256 | - |
dc.citation.endPage | 1264 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | ORGAN SIZE | - |
dc.subject.keywordPlus | CANCER STATISTICS | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | VARIANCE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | SUBTYPES | - |
dc.subject.keywordPlus | MARKERS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.